EUR 50,000 to 60,000 : CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences: The Biomedical Sequencing Facility is Austria’s leading technology platform and service provider for genomics in biomedicine Vienna (AT)

Funding Opportunity PAR-19-366 from the NIH Guide for Grants and Contracts. The purpose of the Institutional Research and Academic Career Development Award (IRACDA) Program is to develop a diverse pool of well-trained scientists available to address the nation's biomedical research agenda. The program requires effective partnerships between a research-intensive institution and a teaching-intensive partner institution that has a historical mission or a demonstrated commitment to educating students from groups underrepresented in the biomedical research workforce. The IRACDA program provides support for a mentored postdoctoral research training experience at the research-intensive institution and funding for the IRACDA scholars to develop critical teaching and mentoring skills at a partner institution. The primary goals of the IRACDA program are to develop a diverse pool of well-trained biomedical scientists who have the necessary knowledge and skills to pursue independent academic careers and to enhance science educational offerings at partner institutions. This Funding Opportunity Announcement (FOA) does not allow appointed scholars to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

Notice NOT-HS-19-020 from the NIH Guide for Grants and Contracts

Notice NOT-MH-19-039 from the NIH Guide for Grants and Contracts

Notice NOT-TR-19-027 from the NIH Guide for Grants and Contracts

Notice NOT-HD-19-026 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-371 from the NIH Guide for Grants and Contracts. The purpose of the NIAID Career Transition Award (CTA) program is to assist postdoctoral fellows' transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

Notice NOT-HL-19-709 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-19-015 from the NIH Guide for Grants and Contracts. The Prevention of Lower Urinary tract Symptoms (PLUS) Research Consortium will use qualitative and quantitative strategies to conduct collaborative, transdisciplinary studies to establish the scientific basis for future intervention studies to promote bladder health and prevent lower urinary tract symptoms (LUTS) and associated bladder conditions such as bladder infections, urinary incontinence, voiding dysfunction, overactive bladder and interstitial cystitis/bladder pain syndrome in adolescent and adult women across the life course. This FOA is to invite applications for Clinical Research Centers to build on foundational work to establish a longitudinal cohort study with the intent of identifying plausible targets for future intervention studies. The consortium will also conduct a range of additional studies to facilitate the success of future intervention and implementation studies.

Funding Opportunity RFA-DK-19-016 from the NIH Guide for Grants and Contracts. The Prevention of Lower Urinary tract Symptoms (PLUS) Research Consortium will use qualitative and quantitative strategies to conduct collaborative, transdisciplinary studies to establish the scientific basis for future intervention studies to promote bladder health and prevent lower urinary tract symptoms (LUTS) and associated bladder conditions such as bladder infections, urinary incontinence, voiding dysfunction, overactive bladder and interstitial cystitis/bladder pain syndrome in adolescent and adult women across the life course. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for the Scientific and Data Center to build on foundational work to establish a longitudinal cohort study with the intent of identifying plausible targets for future intervention studies. The consortium will also conduct a range of additional studies to facilitate the success of future intervention and implementation studies.

Funding Opportunity RFA-CA-19-051 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to currently funded NCI Specialized Center--Cooperative Agreements that will inform on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.

Negotiable: Paramount Recruitment: Senior Biostatistician - Drug Discovery Due to successfully winning major international research projects, an award winning biotech based in Cambridge is expanding, has released a number of fantastic opportunities in their Bioinformatics team. Cambridge, England

Competitive Salary: EMBL: Bioinformatician Location: EMBL- Cambridge, Cambridgeshire, England

Funding Opportunity RFA-HD-20-020 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to address the needs of the maternal and pediatric HIV scientific community for research data translation and sharing. This initiative will support secondary data analyses using archived HIV/AIDS data and specimens to generate new research questions and findings relevant to the scientific mission and priorities of the NICHD, Maternal and Pediatric Infectious Disease Branch(MPIDB) and Office of AIDS Research (OAR). The goal of this initiative is to continue the encouragement of the scientific community to utilize HIV/AIDS archived data sets and specimen collections to answer important questions about the epidemiology, pathogenesis, treatment, clinical manifestations and complications of HIV/AIDS in maternal, pediatric and adolescent populations.

Notice NOT-HL-19-719 from the NIH Guide for Grants and Contracts

Notice NOT-AT-19-034 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-19-049 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded R01 Research Project Grants that will inform on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.

Funding Opportunity RFA-CA-19-050 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to ongoing NCI-funded U01 Research Project Grants that will inform on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.

Funding Opportunity RFA-CA-19-052 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to currently funded NCI Research Program Projects that will inform on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level.

Funding Opportunity RFA-CA-19-053 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support the addition of new aims and directions to currently funded NCI P50 Specialized Research Center grants that will inform on underlying mechanisms of resistance, preclinical design and foster development of single or combination therapies to effectively target resistant/refractory tumors and/or their microenvironment at the clinical level